Medical Oncology

Non-melanoma skin cancer

Questions discussed in this category

Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

4 Answers available

Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?

Do you base your decision on extent of residual disease? Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...

4 Answers available

Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?

Is a placebo-controlled trial anticipated?

6 Answers available

Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?

3 Answers available

What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?

3 Answers available

What clinical or pathologic features would make you more concerned that a new skin SCC is from metastatic disease or a new cutaneous primary?

1 Answer available

Papers discussed in this category

N Engl J Med, 2022 Sep 12

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

Front Oncol, 2023 Jan 04

Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.

Br J Dermatol, 2015 Aug 08

Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.

J. Clin. Oncol., 2018 Mar 14

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Related Topics in Medical Oncology